AP 22161
Latest Information Update: 07 Sep 2021
At a glance
- Originator ARIAD Pharmaceuticals
- Class Osteoporosis therapies
- Mechanism of Action Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
- 12 Nov 2003 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (unspecified route)
- 11 Mar 2003 No development reported - Preclinical for Postmenopausal osteoporosis in USA (unspecified route)